AACR22: CAR T-cell therapy/ mRNA vaccine combination exhibits efficacy for solid tumors

According to preliminary data from a Phase I/II trial, a CAR T-cell product in combination with an mRNA vaccine exhibits an acceptable safety profile and shows early signs of efficacy in patients with solid tumors. The findings were recently presented at the AACR 2022 Annual Meeting (8−13 April 2022; LA, USA). The CAR T-cell product being studied targets CLDN6, a tumor-specific antigen widely expressed in solid tumors. Whilst the mRNA vaccine is termed CARVac and encodes CLDN6, which favors the expansion of the CAR T cells. The combination of the two has been named BNT211. You may also be interested...